“Temporarily Unshackled Private Sector Responds to Demand for More Coronavirus Tests” By Jeffrey Singer, courtesy of the Cato Institute I and others have attributed much of the initially flat‐footed response of public health officials to the coronavirus pandemic to cumbersome, inflexible, and outdated regulations controlling the development and distribution of drugs and tests. As I pointed […]
Tag: Eli Lilly
Analyzing health records, insurance claims speeds new treatments
Historically the trove of medical and para-medical information known as “real-world evidence,” including health records but also insurance claims and patient registries, has mostly been used as a source for additional evaluation of the efficacy of existing drugs after they have already been approved. But […]
Want to cure Alzheimer’s? Fix IP laws
The last few years have brought a slew of new treatments (and sometimes cures) for fatal and chronic diseases long considered almost untreatable, including various cancers, diabetes, and heart disease. But one foe has remained seemingly intractable: dementia associated with old age, particularly Alzheimer’s. […]